MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.50
-0.62
-2.37%
After Hours: 25.50 0 0.00% 17:43 07/10 EDT
OPEN
27.89
PREV CLOSE
26.12
HIGH
28.25
LOW
25.21
VOLUME
2.11M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
7.73
MARKET CAP
1.52B
P/E (TTM)
-11.3626
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYTK stock price target is 30.71 with a high estimate of 35.00 and a low estimate of 23.00.

EPS

CYTK News

More
Benzinga's Top Upgrades, Downgrades For July 10, 2020
Benzinga · 7h ago
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 10h ago
Raymond James Initiates Coverage On Cytokinetics with Strong Buy Rating, Announces Price Target of $39
Raymond James analyst Dane Leone initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Strong Buy rating and announces Price Target of $39.
Benzinga · 11h ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 1d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 2d ago
Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $35
Morgan Stanley maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $29 to $35.
Benzinga · 3d ago
Missed the biotech breakout? These stocks in the industry are still set to run, MKM says
Biotechnology stocks have ripped higher in 2020 and some investors might have missed their chance to capitalize on the surge.
CNBC.com · 07/03 12:37
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
SOUTH SAN FRANCISCO, Calif., July 01, 2020 -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a Virtual Investor and Analyst Day on Wednesday, July.
GlobeNewswire · 07/01 20:00

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About CYTK

Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, reldesemtiv, and spinal muscular atrophy (SMA), CK-3773274 (CK-274).
More

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.